Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00112073 · ClinicalTrials.gov registry record · Phase 2

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

A Phase 2 study of Alzheimers Disease, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.

Completed
Registry status
Phase 2
Development phase
234
Enrollment target
20
Study locations

NCT00112073: Completed Phase 2 study of Alzheimers Disease, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.

NCT00112073 is a Phase 2 study of Alzheimers Disease that has completed, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 234 participants, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00112073, a Phase 2 study of Alzheimers Disease, has completed, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.

COMPLETED
Registry status
Phase 2
Development phase
234 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).

Conditions Studied

Alzheimers Disease

Interventions

  • OTHER placebo
  • DRUG bapineuzumab

Study Locations (20)

California

  • UC Irvine - Irvine
  • Pharmacology Research Institute - Los Alamitos
  • Pharmacology Research Institute - Northridge
  • UCSD Shiley-Marcos Alzheimer's Disease Research Center - San Diego
  • Memory & Aging Center, UCSF - San Francisco

Florida

  • Brain Matters Research, Inc. - Delray Beach
  • Mayo Clinic - Department of Neurology - Jacksonville

New York

  • Sergievsky Center, Columbia University - New York
  • University of Rochester / Monroe Community Hospital - Rochester

Arizona

  • Cleo Roberts Center for Clinical Research / Sun Health Research Institute - Sun City

Connecticut

  • Yale University School of Medicine - New Haven

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Illinois

  • Rush Presbyterian St. Luke's Medical Center - Chicago

Indiana

  • Department of Neurology - Indiana University Medical Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 234 participants
Start Date 2005-04
Est. Completion 2008-12
Phase Phase 2

Sponsor

JANSSEN Alzheimer Immunotherapy Research & Development

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00112073

The ClinicalTrials.gov registry entry for NCT00112073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (94% lower). The listed sponsor is JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00112073 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT00112073 about?

NCT00112073 is a clinical study titled "AAB-001 in Patients With Mild to Moderate Alzheimer's Disease". The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).

What is the current status of trial NCT00112073?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2005-04. Estimated completion is 2008-12.

What conditions does trial NCT00112073 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT00112073?

The interventions under investigation include: placebo (OTHER), bapineuzumab (DRUG).

Who is sponsoring clinical trial NCT00112073?

This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00112073 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.